A targeted low molecular weight near-infrared fluorescent probe for prostate cancer

58Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Prostate-specific membrane antigen (PSMA) remains an active target for imaging and therapeutic applications for prostate cancer. Although radionuclide-based imaging is generally more sensitive and also has been deeply explored, near-infrared fluorescence imaging agents are simple to prepare and compatible with long-term storage conditions. In the present study, a near-infrared fluorescent imaging probe (Cy5.5-CTT-54.2) has been developed by chemical conjugation of Cy5.5N-hydroxysuccinimide ester (Cy5.5-NHS) with a potent PSMA inhibitor CTT-54.2 (IC50 = 144 nM). The probe displays a highly potency (IC50 = 0.55 nM) against PSMA and has demonstrated successful application for specifically labeling PSMA-positive prostate cancer cells in both two and three-dimensional cell culture conditions. These results suggest that the potent, near-infrared Cy5.5-PSMA inhibitor conjugate may be useful for the detection of prostate tumor cells by optical in vivo imaging. © 2010 Elsevier Ltd. All rights reserved.

Cite

CITATION STYLE

APA

Liu, T., Wu, L. Y., Hopkins, M. R., Choi, J. K., & Berkman, C. E. (2010). A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorganic and Medicinal Chemistry Letters, 20(23), 7124–7126. https://doi.org/10.1016/j.bmcl.2010.09.057

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free